Abstract: An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2?. The above-described polypeptide may be introduced directly into a cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into a cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since ErbB2 is involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

Abstract: An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2?. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

Abstract: An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2?. The above-described polypeptide may be introduced directly into a cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into a cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since ErbB2 is involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

Abstract: An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2?. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

Abstract: A variety of chimeric plasmids each of which comprises (a) a tetracycline resistance gene (Tc) deriving from pAM.alpha.1, one of the plasmids retained by Streptococcus faecalis, (b) an ampicillin resistance gene (Amp) deriving from pACYC177, one of the vectors applicable to Escherichia coli and (c) either or both of origins, an origin (OripAM.alpha.1) deriving from the plasmid pAM.alpha.1 and an origin (Ori177) deriving from the vector pACYC177, the tetracycline resistance gene existing on each of which has the unique cleavage site for the restriction enzyme BalI on the entire DNA of the same plasmid and the ampicillin resistance gene existing on each of which has the unique cleavage sites for respective restriction enzymes BglI and PstI on the entire DNA on the same plasmid.There is also provided a chimeric plasmid vector containing (a) a tetracycline resistance gene region (Tc) derived from the plasmid pAM.alpha.

Abstract: A household humidifier comprising a closed water tank, a demineralizer, an air exchange pipe for introducing the outside air, a housing defining a chamber, and a coiled spring. The demineralizer has a container containing ion-exchange resin. The water tank has a water supply port through which the demineralizer and the air exchange pipe can be inserted into the tank. One hollow end of the container is rotatably connected to the chamber such that the container is in communication with the chamber. The container is biased downward by the spring so that the container always lies on its side.

Abstract: A sample yarn-collecting apparatus for preparing a continuous yarn knotted in an end-to-end manner, in which sample yarns having a certain length are collected from a plurality of yarn packages, each of them are connected in succession in an end-to-end manner to obtain one continuous yarn, and the continuous yarn is wound temporarily and thereafter continuously unwound to be fed to testing means while storing it in a quantity within a predetermined range, is disclosed. This apparatus comprises sample yarn collecting means for collecting sample yarns from packages and connecting each of them to form one continuous yarn, means for storing the continuous yarn fed from said collecting means on a rotary member by winding it and feeding the continuous yarn wound and stored on the rotary member to testing means by unwinding it, and supplementary means for controlling the above two means.

Abstract: An improved method for commencing the yarn forming operation of a fasciated yarn and an apparatus for carrying it out thereof. In the apparatus for manufacturing a fasciated yarn from a bundle of fibers suppled from a supply mechanism into a yarn forming mechanism provided with a fluid nozzle, when the yarn forming operation is commenced, the distance between the downstream nip point of the fiber bundle supply mechanism and a twisting point of the fluid nozzle is shortened in a condition shorter than a predetermined distance such as an effective fiber length of a material fiber, and after completion of such initial yarn forming operation, the above-mentioned distance is gradually or stepwisely enlarged to the distance wherein a normal yarn forming operation is carried out. Such shortening and enlarging the above-mentioned distance is carried out by displacing the fluid nozzle and/or changing the position of the downstream nip point of the fiber bundle supply mechanism.